Efficacy of Trimebutine Maleate in the Treatment of Functional Dyspepsia in Childhood

Authors

  • Alexander A Nijevitch Bashkortostan State Medical University
  • Elsa N Akhmadeeva Bashkortostan State Medical University
  • Valery U Sataev Bashkortostan State Medical University
  • Bulat Idrisov Bashkortostan State Medical University

DOI:

https://doi.org/10.3126/jnps.v33i2.7229

Keywords:

Functional dyspepsia, Trimebutine, Opioid agonist, Dyspepsia

Abstract

Peripheral μ-, k- and δ-opioid agonist trimebutine maleate is considered to be an effective therapeutic drug for the treatment of functional gastrointestinal disorders. Ninety-two paediatric outpatients (12- 17 year-old) suffering from functional dyspepsia (epigastric pain and meal-induced dyspeptic symptoms) were enrolled in a prospective openlabel study. For ethical reasons, no placebo group was included. Patients were treated with trimebutine maleate (200 mg three times daily). After a 3-week treatment there was a significant decrease in scores of epigastric pain (p<0.05), postprandial fullness (p<0.05), early satiety (p<0.05), nausea (p<0.05) and belching (p<0.05). The treatment regimen was well tolerated and demonstrated a good compliance. In conclusion, we postulate that trimebutine maleate is an effective medication for relief of main symptoms associated with functional dyspepsia syndrome in childhood. Because of the limited data on therapeutic interventions in functional dyspepsia in childhood and increasing demand for therapies to treat this disorder, further evaluation of the efficacy of trimebutine treatment for children is certain.

DOI: http://dx.doi.org/10.3126/jnps.v33i2.7229  

J Nepal Paediatr Soc. 2013; 33(2):158-162

Downloads

Download data is not yet available.
Abstract
1584
PDF
1681

Author Biography

Alexander A Nijevitch, Bashkortostan State Medical University

Assistant Professor, Chair of Paediatrics

Downloads

Published

2013-10-07

How to Cite

Nijevitch, A. A., Akhmadeeva, E. N., Sataev, V. U., & Idrisov, B. (2013). Efficacy of Trimebutine Maleate in the Treatment of Functional Dyspepsia in Childhood. Journal of Nepal Paediatric Society, 33(2), 158–162. https://doi.org/10.3126/jnps.v33i2.7229

Issue

Vol. 33 No. 2 (2013)

Section

Novel Therapy

License

Authors who publish with this journal agree to the following terms:

Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.

Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.

Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).